NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological...
NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological...
NeuroSense Therapeutics Announces Biomarker Data From ALS Phase 2b Clinical Trial; Met Its Safety And Efficacy Endpoints Including Reducing Functional And Respiratory Deterioration And Statistically Significant Changes In ALS-Related Biological Markers Indicating PrimeC's Biological Activity
NeuroSense Therapeutics宣佈來自ALS第二期臨床試驗的生物標誌物數據；滿足其安全性和療效終點，包括減少功能和呼吸惡化，並對與ALS相關的生物標誌物產生顯着統計的變化，表明PrimeC的生物活性。
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation
12個月的數據展示出鐵含量的調節，與改善ALS生存率和疾病緩解相一致。
Previous results showed PrimeC slowed disease progression by 36% and improved survival rates, highlighting its potential as a transformative ALS therapy
之前的結果顯示，PrimeC將疾病進展放慢36％並改善了生存率，突顯其作爲一種具有轉化性的ALS治療方案可能性。
CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announces positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). This data provides additional insights that align with the Company's recent announcements of improved survival by 43% and slowed disease progression by 36%.
美國馬薩諸塞州劍橋市，2024年8月1日 /美通社/-- 神經感知治療有限公司（NASDAQ納斯達克股票代碼：NRSN）(“神經感知”)，一家開發用於治療嚴重神經退行性疾病的新型治療方案的生物技術公司，宣佈來自於PARADIGM第二期研究的12個月的正面的鐵生物標記物數據。該研究評估了PrimeC在患有肌萎縮側索硬化症的人群中的安全性和療效。該數據提供了額外的見解，與該公司最近宣佈的改善生存率43％和減緩疾病進展36％相一致。
